                         SEQUENCE LISTING

<110>  MEDIMMUNE LIMITED
       
 
<120>  GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF CHRONIC KIDNEY DIESEASE AND DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES

<130>  2943.1440002

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Homo sapiens

<400>  1

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  2
<211>  30
<212>  PRT
<213>  Homo sapiens

<400>  2

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 
            20                  25                  30  


<210>  3
<211>  31
<212>  PRT
<213>  Homo sapiens

<400>  3

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  30      


<210>  4
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  chimeric GLP-1/glucagon peptide


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine with a palmitoyl group conjugated to the epsilon 
       nitrogen,through a gamma glutamic acid linker

<400>  4

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Glu Tyr Leu Asp Ser 
1               5                   10                  15      


Glu Arg Ala Arg Asp Phe Val Ala Trp Leu Glu Ala Gly Gly 
            20                  25                  30  


